^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gPD-L1 CAR-T

    i
    Other names: gPD-L1 CAR-T
    Associations

    News

    Trials
    Company:
    Topmunnity Therap
    Drug class:
    PD-L1-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Non-autonomous enhancement of gPDL1 CAR-T annihilates TNBC development (AACR 2023)
    Despite the excellent anti-cancer activity, the atezolizumab-based chimeric antigen receptor (CAR) T cells showed a robust off-target effect. Overall, gPD-L1 CAR-T exhibits excellent anti-tumor activity against TNBCs, and it could be a promising immunotherapy tool to treat TNBCs in clinic. Furthermore, targeting glycosylation moiety on the tumor antigen is a novel approach to lessen CAR-T toxicity in patients.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    PD-L1 expression • PD-L1 amplification
    |
    Tecentriq (atezolizumab) • gPD-L1 CAR-T